Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $148.58M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
Returns on capital
Abeona Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
44.7%
avg -94.6%
ROIC
-44.0%
avg -58.1%
ROA
32.4%
avg -41.3%
Analysis
ROE is currently the strongest return metric at 44.7% versus its period average of -94.6%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Vishwas Seshadri | President, Chief Executive Officer & Director | USD 1.52M | 50 | 1.29M | 2.26% |
Joseph Walter Vazzano | Chief Financial Officer | USD 898.47K | 42 | 482.89K | 0.85% |
Brendan O'Malley | Chief Legal Officer | USD 783.93K | 57 | — | — |
Madhav Vasanthavada | Senior Vice President, Chief Commercial Officer & Head of Business Development | — | 47 | 285.72K | 0.50% |
Brian Kevany | Chief Technical & Scientific Officer | — | — | — | — |
Carl Denny | Senior Vice President of Regulatory Affairs | — | — | — | — |
Gianine Esposito | Senior VP & Chief People Officer | — | — | — | — |
Gregory Gin | Vice President of Investor Relations & Corporation Communications | — | — | — | — |
Jon Voss | Vice President & Head of Quality | — | 66 | — | — |
Megan Callan | Vice President & Head of Quality | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 29, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
37
$3.50M
Net Transaction Value
−$3.50M
Net selling
Most Active
Vazzano Joseph Walter
8 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 29, 26Sep 29, 2026 | Seshadri Vishwas Direct | Sell | $101.1K$101,091.00 |
| Sep 29, 26Sep 29, 2026 | Vasanthavada Madhav Direct | Sell | $25.3K$25,272.75 |
| Sep 29, 26Sep 29, 2026 | Vazzano Joseph Walter Direct | Sell | $47.4K$47,385.12 |
| Sep 29, 26Sep 29, 2026 | O'Malley Brendan M. Direct | Sell | $34.7K$34,681.72 |
| Sep 1, 26Sep 1, 2026 | Alvino Mark Direct | Sell | $88K$87,966.00 |
| Jul 21, 26Jul 21, 2026 | Vazzano Joseph Walter Direct | Sell | $9.7K$9,651.34 |
| Jul 9, 26Jul 9, 2026 | Vasanthavada Madhav Direct | Sell | $87.8K$87,784.40 |
| Jul 9, 26Jul 9, 2026 | Vazzano Joseph Walter Direct | Sell | $173.3K$173,256.86 |
| Jul 9, 26Jul 9, 2026 | Seshadri Vishwas Direct | Sell | $473.3K$473,329.65 |
| Jul 9, 26Jul 9, 2026 | O'Malley Brendan M. Direct | Sell | $83.9K$83,912.59 |
1–10 of 37
Summary
Insiders reported 0 buys worth $0.00 and 37 sells worth $3.50M over the last 12 months. That adds up to net selling of $3.50M. Vazzano Joseph Walter was the most active insider with 8 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +11.6% (5yr)1 analysts |
| Revenue | N/A | N/A | +60.3% | +124.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | +10.2% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +60.3% over three years. Forward estimates point to Revenue at +124.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Abeona Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ABEO's management, answered from reported figures.
Who manages ABEO?
Abeona Therapeutics Inc. (ABEO) lists 10 active executives. The top listed executive is Brendan O'Malley, Chief Legal Officer.
Are ABEO insiders buying or selling?
Recent insider activity shows net selling of $4.32M.
Continue the stock analysis
Jump to another research area for this company.